Ross Maclean, MD, PhD, MBA
Senior Vice President and Head of Medical Affairs
As the Head of Medical Affairs, Dr. Maclean is responsible for medical support for PHE health policy and economic research, and the business development efforts required to secure the work. In addition, for the wider Precision Medicine Group family of companies, Dr. Maclean leads the development of medical strategies and products, and scientific support for Precision Value & Health and Precision Effect. Dr. Maclean has more than 20 years of progressive experience in health services and outcomes research, health economics, health system design, health policy, and market access. With 12 years spent in the biopharmaceutical industry, he gained wide exposure to the R&D environment as a leader of the global Health Economics and Outcomes Research (HEOR) function for cardiovascular, metabolics, and immunology products. Dr. Maclean held the positions of VP, US HEOR, VP, Cardiovascular and Diabetes Medical, at Bristol-Myers Squibb.
MB, ChB, University of Aberdeen
MD, University of Aberdeen
MBA, University of Aberdeen
MSc, Health Services & Public Health Research, with Distinction, University of Aberdeen
- Lakdawalla DN, et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012.
- Philipson TJ, et al. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care. 2010.
- Seabury SA, et al. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood). 2012.
- Yin W, et al. Value of survival gains in chronic myeloid leukemia. Am J Manag Care. 2012.